Immune Checkpoint Inhibitors Clinical Trial
Official title:
Fertility and Pregnancy After Avelumab Treatment
Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 agents, initially evaluated in advanced non-curative pathologies, are now being evaluated in adjuvant or even neoadjuvant curative treatment conditions. This paradigm shift is leading to the treatment of young women, particularly in the context of gestational trophoblastic tumours. Given the potential autoimmune side-effects affecting endocrine functions, as well as their impact on maternal-foetal tolerance mechanisms, accurate assessment of post-ICT fertility is necessary. In the coming years, treatment with anti-PD-L1 (avelumab) could become a cornerstone of the therapeutic strategy for patients with gestational trophoblastic tumours. However, these patients are often young and of childbearing age, so safety of use in terms of fertility and successful pregnancies is an essential factor in the widespread use of immunotherapy as a treatment option. Some studies have reported the possibility of conceiving after avelumab treatment, but no cohort has been reported. This study aims to explore fertility and the course of potential pregnancy in 50 patients treated with anti-PD-L1 (avelumab) over the last 5 years in several French centres.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05123287 -
A Perspective, Self-control Study on the Progression of Carotid Plaques in Anti-PD-1 mAb Treated Tumor Patients by Artery Ultrasound Follow-up
|
||
| Recruiting |
NCT06124378 -
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
|
Phase 2 | |
| Recruiting |
NCT05260606 -
Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer
|
||
| Recruiting |
NCT04808817 -
Relationship Between Immunity and Metabolism in Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer. ( RIMEC )
|
N/A | |
| Recruiting |
NCT05310383 -
Tislelizumab and Radiotherapy for Recurrent Cervical Cancer
|
Phase 2 | |
| Recruiting |
NCT05310305 -
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
|
||
| Recruiting |
NCT05273255 -
Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy
|
N/A | |
| Recruiting |
NCT05290935 -
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial
|
Phase 2 | |
| Not yet recruiting |
NCT06279403 -
Upfront Immune Checkpoint Inhibitors With Deferred Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05477979 -
The Associations of Psychological Stress With Therapy Efficacy and Prognosis of Lung Cancer (STRESS-LUNG)
|
||
| Recruiting |
NCT05813418 -
Identification of Predictive Biomarkers for Immune-Related Adverse Events (irAEs) in Patients Undergoing Immune CheckPoint Inhibitors (ICPI) Treatment
|
N/A | |
| Active, not recruiting |
NCT05863052 -
Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population
|
||
| Active, not recruiting |
NCT04670445 -
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
|
N/A | |
| Recruiting |
NCT05288569 -
irAE Prediction of Anti-PD-1/L1 in Lung Cancer
|
||
| Recruiting |
NCT05349058 -
Assessment of Myocardial Injury in Patients Treated With Immune Checkpoint Inhibitors
|
||
| Recruiting |
NCT04826406 -
A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs).
|
Phase 2 | |
| Recruiting |
NCT06040177 -
Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06114940 -
Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC
|
Phase 2 | |
| Active, not recruiting |
NCT03948724 -
Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology
|
N/A | |
| Not yet recruiting |
NCT05898256 -
Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
|
Phase 1/Phase 2 |